

# Ruth Ann Marrie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3284007/publications.pdf>

Version: 2024-02-01

421  
papers

23,904  
citations

12303

69  
h-index

10708

138  
g-index

424  
all docs

424  
docs citations

424  
times ranked

17481  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
2	Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1816-1821.	1.4	965
3	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.5	765
4	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. <i>Multiple Sclerosis Journal</i> , 2008, 14, 383-390.	1.4	535
5	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 777-788.	1.5	406
6	Incidence and prevalence of multiple sclerosis in Europe: a systematic review. <i>BMC Neurology</i> , 2013, 13, 128.	0.8	392
7	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 305-317.	1.4	381
8	Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. <i>Neurology</i> , 2010, 74, 1041-1047.	1.5	366
9	Environmental risk factors in multiple sclerosis aetiology. <i>Lancet Neurology</i> , The, 2004, 3, 709-718.	4.9	290
10	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. <i>Neurology</i> , 2004, 63, 2039-2045.	1.5	275
11	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. <i>Multiple Sclerosis Journal</i> , 2015, 21, 263-281.	1.4	273
12	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. <i>Lancet Neurology</i> , The, 2011, 10, 436-445.	4.9	267
13	The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. <i>Neurology</i> , 2010, 74, 465-471.	1.5	252
14	Validity of performance scales for disability assessment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1176-1182.	1.4	237
15	Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 511-517.e1.	2.4	222
16	Comorbidity delays diagnosis and increases disability at diagnosis in MS. <i>Neurology</i> , 2009, 72, 117-124.	1.5	213
17	Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. <i>JAMA Neurology</i> , 2020, 77, 82.	4.5	213
18	The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. <i>Multiple Sclerosis Journal</i> , 2009, 15, 385-392.	1.4	191

#	ARTICLE	IF	CITATIONS
19	Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review. <i>Neuroepidemiology</i> , 2013, 40, 195-210.	1.1	169
20	Comorbidity, socioeconomic status and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1091-1098.	1.4	168
21	Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 360-368.	0.9	166
22	Effect of comorbidity on mortality in multiple sclerosis. <i>Neurology</i> , 2015, 85, 240-247.	1.5	163
23	Does multiple sclerosis-associated disability differ between races?. <i>Neurology</i> , 2006, 66, 1235-1240.	1.5	162
24	Resting state sensorimotor functional connectivity in multiple sclerosis inversely correlates with transcallosal motor pathway transverse diffusivity. <i>Human Brain Mapping</i> , 2008, 29, 818-827.	1.9	162
25	Comorbidity in multiple sclerosis: implications for patient care. <i>Nature Reviews Neurology</i> , 2017, 13, 375-382.	4.9	161
26	MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. <i>Lancet Neurology</i> , The, 2011, 10, 1065-1073.	4.9	159
27	Emerging effects of comorbidities on multiple sclerosis. <i>Lancet Neurology</i> , The, 2010, 9, 820-828.	4.9	156
28	Health-related quality of life in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1417-1424.	1.5	156
29	Diet quality is associated with disability and symptom severity in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1-e11.	1.5	149
30	Depression in multiple sclerosis. <i>International Review of Psychiatry</i> , 2017, 29, 463-472.	1.4	146
31	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	3.7	139
32	Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis. <i>Neuroepidemiology</i> , 2010, 35, 83-90.	1.1	138
33	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1316-e1323.	1.5	136
34	High frequency of adverse health behaviors in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 105-113.	1.4	135
35	Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 12-26.	0.9	133
36	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 282-293.	1.4	131

#	ARTICLE	IF	CITATIONS
37	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 318-331.	1.4	131
38	Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. <i>Journal of Psychosomatic Research</i> , 2017, 101, 17-23.	1.2	131
39	Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. <i>BMC Neurology</i> , 2013, 13, 16.	0.8	122
40	Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought. <i>Journal of Medical Internet Research</i> , 2013, 15, e67.	2.1	121
41	2010 McDonald criteria for diagnosing pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2012, 72, 211-223.	2.8	117
42	The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 9-15.	0.9	113
43	Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 122, 115-128.e1.	2.4	113
44	Association of fatigue and brain atrophy in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005, 228, 161-166.	0.3	111
45	Validation of the NARCOMS registry: diagnosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 770-775.	1.4	111
46	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
47	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1310-1319.	1.4	109
48	Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. <i>Neurology</i> , 2018, 90, 789-800.	1.5	107
49	Differences in the burden of psychiatric comorbidity in MS vs the general population. <i>Neurology</i> , 2015, 85, 1972-1979.	1.5	106
50	Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 445-451.	4.9	105
51	High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991â€“2010). <i>Journal of Neurology</i> , 2015, 262, 2352-2363.	1.8	100
52	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 342-349.	1.4	100
53	Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 970-978.	1.5	100
54	Validity and reliability of the MSQ LI in cognitively impaired patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 621-626.	1.4	97

#	ARTICLE	IF	CITATIONS
55	Under Treatment of Overactive Bladder Symptoms in Patients With Multiple Sclerosis: An Ancillary Analysis of the NARCOMS Patient Registry. <i>Journal of Urology</i> , 2010, 183, 1432-1437.	0.2	97
56	Multiple sclerosis and antecedent infections. <i>Neurology</i> , 2000, 54, 2307-2310.	1.5	92
57	Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 333-342.	1.8	91
58	The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 610-616.	1.4	90
59	Dramatically changing rates and reasons for hospitalization in multiple sclerosis. <i>Neurology</i> , 2014, 83, 929-937.	1.5	89
60	Sex differences in comorbidity at diagnosis of multiple sclerosis. <i>Neurology</i> , 2016, 86, 1279-1286.	1.5	86
61	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 191-204.	2.7	86
62	The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1867-1875.	0.9	84
63	Changes in the ascertainment of multiple sclerosis. <i>Neurology</i> , 2005, 65, 1066-1070.	1.5	80
64	Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1050-1056.	0.9	80
65	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 294-304.	1.4	79
66	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1287-1295.	1.5	79
67	Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , 2019, 92, .	1.5	79
68	Comorbidity increases the risk of hospitalizations in multiple sclerosis. <i>Neurology</i> , 2015, 84, 350-358.	1.5	77
69	Comorbidity increases the risk of relapse in multiple sclerosis. <i>Neurology</i> , 2017, 89, 2455-2461.	1.5	77
70	Infection-related health care utilization among people with and without multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1506-1516.	1.4	76
71	Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 425-434.	0.5	75
72	Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 69-75.	1.4	73

#	ARTICLE	IF	CITATIONS
73	Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. <i>General Hospital Psychiatry</i> , 2018, 53, 65-72.	1.2	73
74	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1674-1680.	0.9	73
75	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. <i>Brain</i> , 2019, 142, 617-632.	3.7	72
76	The Multiple Sclerosis Intimacy and Sexuality Questionnaire "re-validation and development of a 15-item version with a large US sample. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1197-1203.	1.4	71
77	A cross-sectional study of bone health in multiple sclerosis. <i>Neurology</i> , 2009, 73, 1394-1398.	1.5	69
78	Validation of an algorithm for identifying MS cases in administrative health claims datasets. <i>Neurology</i> , 2019, 92, e1016-e1028.	1.5	69
79	Predictors of alternative medicine use by multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2003, 9, 461-466.	1.4	68
80	Cumulative impact of comorbidity on quality of life in MS. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 180-186.	1.0	68
81	Association between comorbidity and clinical characteristics of MS. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 135-141.	1.0	67
82	Effects of physical comorbidities on disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e419-e427.	1.5	67
83	Can $T_1$ / $T_2$ ratio be used as a myelin-specific measure in subcortical structures? Comparisons between FSE-based $T_1$ / $T_2$ ratios, GRASE-based $T_1$ / $T_2$ ratios and multi-echo GRASE-based myelin water fractions. <i>NMR in Biomedicine</i> , 2018, 31, e3868.	1.6	66
84	Five years before multiple sclerosis onset: Phenotyping the prodrome. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1092-1101.	1.4	66
85	Disparities in the management of multiple sclerosis-related bladder symptoms. <i>Neurology</i> , 2007, 68, 1971-1978.	1.5	65
86	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1446-1453.	1.5	64
87	The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1285-1293.	0.9	64
88	Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 1130-1139.	1.5	63
89	Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. <i>Current Medical Research and Opinion</i> , 2010, 26, 493-500.	0.9	62
90	The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study. <i>Neuroepidemiology</i> , 2013, 40, 85-92.	1.1	62

#	ARTICLE	IF	CITATIONS
91	Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study. <i>BMC Health Services Research</i> , 2013, 13, 457.	0.9	60
92	Temporal trends in multiple sclerosis prevalence and incidence in a large population. <i>Neurology</i> , 2018, 90, e1435-e1441.	1.5	60
93	The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. <i>PLoS ONE</i> , 2018, 13, e0198975.	1.1	58
94	Use of eHealth and mHealth technology by persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 13-19.	0.9	58
95	An Intervention to Improve Procedure Education for Internal Medicine Residents. <i>Journal of General Internal Medicine</i> , 2008, 23, 288-293.	1.3	57
96	Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2017, 37, 37-48.	0.8	57
97	Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis. <i>NeuroImage</i> , 2006, 32, 1127-1133.	2.1	56
98	Employment and absenteeism in working-age persons with multiple sclerosis. <i>Journal of Medical Economics</i> , 2017, 20, 493-502.	1.0	55
99	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	1.4	55
100	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 23-37.	1.4	55
101	Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England. <i>JAMA Neurology</i> , 2020, 77, 820.	4.5	55
102	The prevalence of multiple sclerosis in 3 US communities. <i>Preventing Chronic Disease</i> , 2010, 7, A12.	1.7	55
103	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 824-831.	0.3	53
104	Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 78-85.	0.9	53
105	General Health Issues in Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 1046-1057.	0.4	52
106	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. <i>Brain</i> , 2017, 140, 1300-1315.	3.7	52
107	Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. <i>Journal of Psychosomatic Research</i> , 2016, 89, 107-113.	1.2	50
108	The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. <i>Multiple Sclerosis Journal</i> , 2021, 27, 6-12.	1.4	50

#	ARTICLE	IF	CITATIONS
109	Epstein-Barr virus in oral shedding of children with multiple sclerosis. <i>Neurology</i> , 2013, 81, 1392-1399.	1.5	48
110	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016, 86, 1437-1445.	1.5	48
111	Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 295-303.	0.3	48
112	The Incidence and Prevalence of Neuromyelitis Optica. <i>International Journal of MS Care</i> , 2013, 15, 113-118.	0.4	47
113	Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. <i>Multiple Sclerosis Journal</i> , 2015, 21, 735-748.	1.4	47
114	Validation of the NARCOMS Registry: fatigue assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 583-584.	1.4	46
115	High rates of physician services utilization at least five years before multiple sclerosis diagnosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1113-1119.	1.4	46
116	A survey of dietary characteristics in a large population of people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 12-18.	0.9	46
117	Intensive care unit admission in multiple sclerosis. <i>Neurology</i> , 2014, 82, 2112-2119.	1.5	45
118	Impact of multiple sclerosis relapse: The NARCOMS participant perspective. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 234-240.	0.9	45
119	A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis. <i>Patient</i> , 2016, 9, 537-546.	1.1	45
120	Evaluating the safety of $\beta$ -interferons in MS. <i>Neurology</i> , 2017, 88, 2310-2320.	1.5	45
121	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 588-596.	1.4	44
122	Monophasic demyelination reduces brain growth in children. <i>Neurology</i> , 2017, 88, 1744-1750.	1.5	43
123	Clinical Features of Dog- and Bat-Acquired Rabies in Humans. <i>Clinical Infectious Diseases</i> , 2013, 57, 689-696.	2.9	42
124	Differing trends in the incidence of vascular comorbidity in MS and the general population. <i>Neurology: Clinical Practice</i> , 2016, 6, 120-128.	0.8	42
125	Five-minute Apgar score as a marker for developmental vulnerability at 5 years of age. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2016, 101, F114-F120.	1.4	42
126	A surface-to-volume gradient of thalamic damage evolves in pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2019, 85, 340-351.	2.8	42



#	ARTICLE	IF	CITATIONS
127	Recovery From Central Nervous System Acute Demyelination in Children. <i>Pediatrics</i> , 2015, 136, e115-e123.	1.0	40
128	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 470-476.	0.9	40
129	Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. <i>BMC Research Notes</i> , 2016, 9, 404.	0.6	40
130	A new way to estimate neurologic disease prevalence in the United States. <i>Neurology</i> , 2019, 92, 469-480.	1.5	40
131	Validation of the NARCOMS Registry: pain assessment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 338-342.	1.4	39
132	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 332-341.	1.4	39
133	Drug Insight: interferon treatment in multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 34-44.	2.7	38
134	Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1464-1471.	1.4	38
135	Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. <i>BMC Research Notes</i> , 2017, 10, 619.	0.6	38
136	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. <i>JMIR Research Protocols</i> , 2018, 7, e15.	0.5	38
137	Fatigue and Comorbidities in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 96-104.	0.4	38
138	Functionalâ€“structural correlations in the afferent visual pathway in pediatric demyelination. <i>Neurology</i> , 2014, 83, 2147-2152.	1.5	37
139	Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study. <i>Interactive Journal of Medical Research</i> , 2014, 3, e3.	0.6	37
140	The Incidence and Prevalence of Thyroid Disease Do Not Differ in the Multiple Sclerosis and General Populations: A Validation Study Using Administrative Data. <i>Neuroepidemiology</i> , 2012, 39, 135-142.	1.1	35
141	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018, 20, 76-84.	0.4	35
142	Parent-of-origin effect in multiple sclerosis. <i>Neurology</i> , 2009, 73, 602-605.	1.5	34
143	Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 355-361.	0.9	34
144	The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results. <i>BMJ Open</i> , 2014, 4, e005718-e005718.	0.8	34

#	ARTICLE	IF	CITATIONS
145	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2252-2269.	1.7	34
146	Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 124-156.	0.9	33
147	Diabetes and anxiety adversely affect cognition in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 164-170.	0.9	33
148	Comorbidity is associated with disease activity in MS. <i>Neurology</i> , 2020, 95, e446-e456.	1.5	33
149	Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome. <i>Multiple Sclerosis Journal</i> , 2021, 27, 290-302.	1.4	33
150	Cancer Incidence and Mortality Rates in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e501-e512.	1.5	33
151	Reliability of Regression-Based Normative Data for the Oral Symbol Digit Modalities Test: An Evaluation of Demographic Influences, Construct Validity, and Impairment Classification Rates in Multiple Sclerosis Samples. <i>Clinical Neuropsychologist</i> , 2014, 28, 281-299.	1.5	32
152	MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 48-60.	0.9	32
153	Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis. <i>International Journal of MS Care</i> , 2017, 19, 240-246.	0.4	32
154	Common variation near IRF6 is associated with IFN- $\gamma$ -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , 2018, 50, 1081-1085.	9.4	32
155	The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. <i>Multiple Sclerosis Journal</i> , 2019, 25, 515-522.	1.4	32
156	The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. <i>BMC Neurology</i> , 2013, 13, 119.	0.8	31
157	Substantial burden of dizziness in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 21-28.	0.9	31
158	Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. <i>Neurology</i> , 2013, 81, 1215-1221.	1.5	31
159	Causes of death among persons with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 484-490.	0.9	31
160	Health insurance affects the use of disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2016, 87, 365-374.	1.5	31
161	Heavy metals, organic solvents, and multiple sclerosis: An exploratory look at gene-environment interactions. <i>Archives of Environmental and Occupational Health</i> , 2016, 71, 26-34.	0.7	30
162	The prevalence of urinary catheterization in women and men with multiple sclerosis. <i>Journal of Spinal Cord Medicine</i> , 2013, 36, 632-637.	0.7	29

#	ARTICLE	IF	CITATIONS
163	A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. <i>European Journal of Neurology</i> , 2016, 23, 1093-1100.	1.7	29
164	The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 165-172.	0.9	29
165	Increased incidence and prevalence of psoriasis in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 81-86.	0.9	28
166	Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 16-21.	0.9	28
167	Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 976-986.	1.4	28
168	Comorbidity in multiple sclerosis: Past, present and future. <i>Clinical and Investigative Medicine</i> , 2019, 42, E5-E12.	0.3	28
169	“Seeing” in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. <i>Multiple Sclerosis Journal</i> , 2013, 19, 953-960.	1.4	27
170	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 685-693.	1.4	27
171	Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 702-711.	0.9	27
172	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. <i>JAMA Network Open</i> , 2021, 4, e2128871.	2.8	27
173	A Population-based Study of Intensive Care Unit Admissions in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 26-33.	1.0	26
174	Incidence and prevalence of MS in children. <i>Neurology</i> , 2018, 91, e1579-e1590.	1.5	26
175	Accuracy of FRAX® in People With Multiple Sclerosis. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1095-1100.	3.1	26
176	A systematic review of morbidities suggestive of the multiple sclerosis prodrome. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 799-819.	1.4	26
177	Care Partners and Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 253-260.	0.4	26
178	Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy. <i>International Journal of MS Care</i> , 2016, 18, 305-310.	0.4	26
179	Children and adolescents adjustment to parental multiple sclerosis: a systematic review. <i>BMC Neurology</i> , 2014, 14, 107.	0.8	25
180	A Practical, Global Perspective on Using Administrative Data to Conduct Intensive Care Unit Research. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1373-1386.	1.5	25

#	ARTICLE	IF	CITATIONS
181	High hypothetical interest in physician-assisted death in multiple sclerosis. <i>Neurology</i> , 2017, 88, 1528-1534.	1.5	25
182	Comorbidity before and after a diagnosis of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 637-651.	1.9	25
183	The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 162-167.	0.9	24
184	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. <i>Brain and Behavior</i> , 2016, 6, e00493.	1.0	24
185	Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1452-1462.	1.4	24
186	Perspectives on marijuana use and effectiveness. <i>Neurology: Clinical Practice</i> , 2017, 7, 333-343.	0.8	24
187	Social Determinants of Outcomes in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 2036-2046.	0.2	24
188	Screening Tools for Anxiety in People with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 273-281.	0.4	24
189	Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 87-92.	0.9	23
190	Identifying priority outcomes that influence selection of disease-modifying therapies in MS. <i>Neurology: Clinical Practice</i> , 2018, 8, 179-185.	0.8	23
191	Prodrome in relapsing&#x2013;remitting and primary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1032-1036.	1.7	23
192	Traditional risk factors may not explain increased incidence of myocardial infarction in MS. <i>Neurology</i> , 2019, 92, e1624-e1633.	1.5	23
193	From the prodromal stage of multiple sclerosis to disease prevention. <i>Nature Reviews Neurology</i> , 2022, 18, 559-572.	4.9	23
194	National estimates of self-reported sitting time in adults with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731875436.	0.5	22
195	Smoking Status over Two Years in Patients with Multiple Sclerosis. <i>Neuroepidemiology</i> , 2009, 32, 72-79.	1.1	21
196	Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1641-1648.	0.9	21
197	Pediatric-onset multiple sclerosis is associated with reduced parental health&#x2013;related quality of life and family functioning. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1661-1672.	1.4	21
198	Smokers with MS have greater decrements in quality of life and disability than non-smokers. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1772-1781.	1.4	20

#	ARTICLE	IF	CITATIONS
199	Multiple sclerosis is associated with low bone mineral density and osteoporosis. <i>Neurology: Clinical Practice</i> , 2019, 9, 391-399.	0.8	20
200	Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 364-369.	0.9	20
201	Machine-learning models for depression and anxiety in individuals with immune-mediated inflammatory disease. <i>Journal of Psychosomatic Research</i> , 2020, 134, 110126.	1.2	20
202	The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 824-31.	0.3	20
203	Validation of the NARCOMS Registry. <i>International Journal of MS Care</i> , 2011, 13, 114-120.	0.4	19
204	Masquerades of Acquired Demyelination in Children. <i>Journal of Child Neurology</i> , 2013, 28, 184-197.	0.7	19
205	Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. <i>General Hospital Psychiatry</i> , 2018, 51, 71-78.	1.2	19
206	Smokers with Multiple Sclerosis Are More Likely to Report Comorbid Autoimmune Diseases. <i>Neuroepidemiology</i> , 2011, 36, 85-90.	1.1	18
207	Vitamin D in MS. <i>Neurology</i> , 2012, 79, 208-210.	1.5	18
208	Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 397-408.	0.8	18
209	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. <i>Neuroepidemiology</i> , 2018, 51, 1-10.	1.1	18
210	Mining healthcare data for markers of the multiple sclerosis prodrome. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 232-240.	0.9	18
211	Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 86-93.	0.9	18
212	The 5-Year Incidence of Mental Disorders in a Population-Based ICU Survivor Cohort. <i>Critical Care Medicine</i> , 2020, 48, e675-e683.	0.4	18
213	Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1200-1208.e1.	2.4	18
214	Validation of NARCOMS Depression Scale. <i>International Journal of MS Care</i> , 2008, 10, 81-84.	0.4	18
215	High or increasing serum NfL is predictive of impending multiple sclerosis relapses. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103535.	0.9	18
216	MS risk in immigrants in the McDonald era. <i>Neurology</i> , 2019, 93, e2203-e2215.	1.5	17

#	ARTICLE	IF	CITATIONS
217	Data harmonization for collaborative research among MS registries: A case study in employment. <i>Multiple Sclerosis Journal</i> , 2021, 27, 281-289.	1.4	17
218	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. <i>Chronic Diseases and Injuries in Canada</i> , 2014, 34, 145-153.	1.4	17
219	Prevalence of neurological conditions across the continuum of care based on interRAI assessments. <i>BMC Health Services Research</i> , 2014, 14, 29.	0.9	16
220	Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1830-1840.	1.4	16
221	Exploring the Implications of Small-Area Variation in the Incidence of Multiple Sclerosis. <i>American Journal of Epidemiology</i> , 2013, 178, 1059-1066.	1.6	15
222	Patient perspectives on switching disease-modifying therapies in the NARCOMS registry. <i>Patient Preference and Adherence</i> , 2014, 8, 971.	0.8	15
223	Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1172-1183.	1.4	15
224	Comorbidity in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 271-272.	0.4	15
225	Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis. <i>Paediatric and Perinatal Epidemiology</i> , 2016, 30, 356-366.	0.8	15
226	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study. <i>PLoS ONE</i> , 2019, 14, e0218215.	1.1	15
227	Lifetime Prevalence and Comorbidity of Mental Disorders in the Two-wave 2002a€™2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): PrÃ©valence et ComorbiditÃ© de DurÃ©e de vie Des Troubles Mentaux Dans lâ€™EnquÃªte de Suivi Sur la SantÃ© Mentale AuprÃ©s des Membres des Forces ArmÃ©es Canadiennes et Des ex-Militaires (ESSMFACM) en Deux Cycles de 2002 Ã 2018. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 070674372110006.	0.9	15
228	The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study. <i>Intensive Care Medicine</i> , 2021, 47, 1450-1461.	3.9	15
229	Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality. <i>Neurology</i> , 2021, 97, e1322-e1333.	1.5	15
230	Change in the Health-Related Quality of Life of Multiple Sclerosis Patients over 5 Years. <i>International Journal of MS Care</i> , 2013, 15, 46-53.	0.4	15
231	Childhood Maltreatment and Psychiatric Comorbidity in Immune-Mediated Inflammatory Disorders. <i>Psychosomatic Medicine</i> , 2022, 84, 10-19.	1.3	15
232	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. <i>Neurology</i> , 2022, 98, .	1.5	15
233	Application of Three Focused Cluster Detection Methods to Study Geographic Variation in the Incidence of Multiple Sclerosis in Manitoba, Canada. <i>Neuroepidemiology</i> , 2014, 43, 38-48.	1.1	14
234	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 8, 86-92.	0.9	14

#	ARTICLE	IF	CITATIONS
235	The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients. <i>Neurological Sciences</i> , 2017, 38, 635-642.	0.9	14
236	Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1093-1101.	0.8	14
237	Factors associated with perceived need for mental health care in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 179-185.	0.9	14
238	Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population-based cohort study. <i>Addiction</i> , 2019, 114, 1791-1799.	1.7	14
239	Psychiatric comorbidity in immune-mediated inflammatory diseases. <i>World Psychiatry</i> , 2021, 20, 298-299.	4.8	14
240	Familial Autoimmune Myasthenia Gravis: Four Patients Involving Three Generations. <i>Canadian Journal of Neurological Sciences</i> , 2000, 27, 307-310.	0.3	13
241	Cerebral arterial and venous blood flow in adolescent multiple sclerosis patients and age-matched controls using phase contrast MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 341-347.	1.9	13
242	Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada. <i>Emerging Infectious Diseases</i> , 2018, 24, 1267-1274.	2.0	13
243	Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1284-1292.	1.4	13
244	Management of diabetes and hypertension in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101987.	0.9	13
245	Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance. <i>Multiple Sclerosis Journal</i> , 2021, 27, 989-1001.	1.4	13
246	Patterns of Attrition in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS). <i>Canadian Journal of Psychiatry</i> , 2021, 66, 996-998.	0.9	13
247	Increased Incidence of Critical Illness Among Patients With Inflammatory Bowel Disease: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2063-2070.e4.	2.4	12
248	Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2019, 102, 1722-1729.	1.0	12
249	Spatial normalization of multiple sclerosis brain MRI data depends on analysis method and software package. <i>Magnetic Resonance Imaging</i> , 2020, 68, 83-94.	1.0	12
250	Rationale and Methodology of the 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): A 16-year Follow-up Survey: Raison D'Être Et Méthodologie De L'enquête De Suivi Sur La Santé Mentale Des Membres Des Forces Armées Canadiennes Et Des Anciens Combattants, 2018 (ESSMFACM). <i>Canadian Journal of Psychiatry</i> , 2021, 66, 942-950.	0.9	12
251	Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 58-64.	0.9	12
252	NARCOMS and Other Registries in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2021, 23, 276-284.	0.4	12

#	ARTICLE	IF	CITATIONS
253	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1697-1709.	1.4	12
254	Predictors of Body Image Related Sexual Dysfunction in Men and Women with Multiple Sclerosis. <i>Sexuality and Disability</i> , 2015, 33, 63-73.	0.4	11
255	Discriminative ability of quality of life measures in multiple sclerosis. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 246.	1.0	11
256	A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. <i>Multiple Sclerosis Journal</i> , 2018, 24, 951-962.	1.4	11
257	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. <i>Multiple Sclerosis Journal</i> , 2019, 25, 980-986.	1.4	11
258	Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 131-140.	1.4	11
259	Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis. <i>Brain</i> , 2021, 144, 162-185.	3.7	11
260	Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852199307.	1.4	11
261	The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , 2021, 145, 110479.	1.2	11
262	Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	11
263	Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	11
264	Multiple Sclerosis and Epstein-Barr Virus. <i>Canadian Journal of Infectious Diseases &amp; Medical Microbiology</i> , 2002, 13, 111-118.	0.3	10
265	Health care utilization before and after intensive care unit admission in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 296-303.	0.9	10
266	Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis. <i>Research in Nursing and Health</i> , 2017, 40, 143-152.	0.8	10
267	Clinical Profile of Persons with Multiple Sclerosis Across the Continuum of Care. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 188-198.	0.3	10
268	Pseudobulbar affect. <i>Neurology: Clinical Practice</i> , 2018, 8, 472-481.	0.8	10
269	The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2020, 27, 1462-1474.	0.9	10
270	Increased mental health care use by mothers of children with multiple sclerosis. <i>Neurology</i> , 2020, 94, e1040-e1050.	1.5	10



#	ARTICLE	IF	CITATIONS
271	Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. <i>CMAJ Open</i> , 2021, 9, E510-E521.	1.1	10
272	Higher Framingham Risk Scores are associated with greater loss of brain volume over time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103088.	0.9	10
273	Examining the Relationship Between Family Caregivers' Emotional States and Ability to Empathize with Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 122-128.	0.4	10
274	Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	10
275	Autoimmune disease and multiple sclerosis: methods, methods, methods. <i>Lancet Neurology</i> , The, 2007, 6, 575-576.	4.9	9
276	Proof of concept studies for tissue-protective agents in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 542-546.	1.4	9
277	Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 360-367.	0.3	9
278	Factors associated with excessive sitting time in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 71-77.	0.9	9
279	Factors associated with receiving bone mineral density screening among people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 305-308.	0.9	9
280	Risk of Mortality in Immigrants with Multiple Sclerosis in Ontario, Canada. <i>Neuroepidemiology</i> , 2020, 54, 148-156.	1.1	9
281	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. <i>Neuroepidemiology</i> , 2020, 54, 140-147.	1.1	9
282	Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample. <i>Frontiers in Neurology</i> , 2020, 11, 621010.	1.1	9
283	Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study. <i>BMJ Open</i> , 2021, 11, e043930.	0.8	9
284	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1948-1959.	1.4	9
285	Pathways to cures for multiple sclerosis: A research roadmap. <i>Multiple Sclerosis Journal</i> , 2022, 28, 331-345.	1.4	9
286	When one and one make three. <i>Neurology</i> , 2008, 70, 1067-1068.	1.5	8
287	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1305-1317.	1.0	8
288	Obesity and HLA in multiple sclerosis: Weighty matters. <i>Neurology</i> , 2014, 82, 826-827.	1.5	8

#	ARTICLE	IF	CITATIONS
289	Caught in a no-win situation: discussions about CCSVI between persons with multiple sclerosis and their neurologists – a qualitative study. <i>BMC Neurology</i> , 2017, 17, 176.	0.8	8
290	Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 57-60.	0.9	8
291	Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1560-1568.	1.4	8
292	Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101440.	0.9	8
293	Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. <i>Crohn's &amp; Colitis 360</i> , 2020, 2, otz053.	0.5	8
294	Support for a non-therapist assisted, Internet-based cognitive-behavioral therapy (iCBT) intervention for mental health in rheumatoid arthritis patients. <i>Internet Interventions</i> , 2021, 24, 100385.	1.4	8
295	Impact of comorbidity on hospitalizations in individuals newly diagnosed with multiple sclerosis: A longitudinal population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101955.	0.9	8
296	Women's Health in Multiple Sclerosis: A Scoping Review. <i>Frontiers in Neurology</i> , 2021, 12, 812147.	1.1	8
297	Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. <i>Chronic Diseases and Injuries in Canada</i> , 2014, 34, 145-53.	1.4	8
298	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103829.	0.9	8
299	Demographic, Genetic, and Environmental Factors That Modify Disease Course. <i>Neurologic Clinics</i> , 2011, 29, 323-341.	0.8	7
300	Patient Recruitment by Neurological Registries. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S23-S26.	0.3	7
301	Hospitalization is associated with subsequent disability in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 23-28.	0.9	7
302	Functional gastrointestinal disorders negatively affect health-related quality of life in MS. <i>Neurology: Clinical Practice</i> , 2019, 9, 381-390.	0.8	7
303	Factors associated with health care utilization in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101511.	0.9	7
304	Uptake and Attitudes About Immunizations in People With Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2021, 11, 327-334.	0.8	7
305	Accuracy of Administrative Hospital Data to Identify Use of Life Support Modalities. A Canadian Study. <i>Annals of the American Thoracic Society</i> , 2020, 17, 229-235.	1.5	7
306	Multiple Sclerosis and the Cancer Diagnosis. <i>Neurology</i> , 2022, 98, .	1.5	7

#	ARTICLE	IF	CITATIONS
307	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , 2017, 48, 124-130.	1.1	6
308	Lower prevalence of multiple sclerosis in First Nations Canadians. <i>Neurology: Clinical Practice</i> , 2018, 8, 33-39.	0.8	6
309	Validation of an algorithm to detect severe MS relapses in administrative health databases. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 134-139.	0.9	6
310	Identifying optic neuritis and transverse myelitis using administrative data. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 258-264.	0.9	6
311	Social phobia in immune-mediated inflammatory diseases. <i>Journal of Psychosomatic Research</i> , 2020, 128, 109890.	1.2	6
312	Health service utilization in immigrants with multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0234876.	1.1	6
313	Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1411-1420.	1.4	6
314	Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2021, 73, 90-99.	1.5	6
315	Breast Cancer Survival in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e13-e22.	1.5	6
316	High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1902-1913.	1.4	6
317	Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. <i>PLoS ONE</i> , 2021, 16, e0249809.	1.1	6
318	Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study. <i>Neurology</i> , 2021, , 10.1212/WNL.0000000000012634.	1.5	6
319	Effect of Physical Comorbidities on Risk of Depression in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2009, 11, 161-165.	0.4	6
320	Disease-modifying drugs for multiple sclerosis and subsequent health service use. <i>Multiple Sclerosis Journal</i> , 2022, 28, 583-596.	1.4	6
321	Unusual Imaging Findings in Progressive Myoclonus Epilepsy. <i>Epilepsia</i> , 2002, 42, 430-432.	2.6	5
322	Design, methodological issues and participation in a multiple sclerosis case-control study. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 197-204.	1.0	5
323	Psychiatric comorbidity in multiple sclerosis: It's not the genes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1803-1805.	1.4	5
324	What is the risk of suicide in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 755-756.	1.4	5

#	ARTICLE	IF	CITATIONS
325	Preventing multiple sclerosis. <i>Neurology</i> , 2017, 89, 1538-1539.	1.5	5
326	Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night. <i>Multiple Sclerosis Journal</i> , 2018, 24, 558-562.	1.4	5
327	Higher health care use before a clinically isolated syndrome with or without subsequent MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 42-49.	0.9	5
328	Mounting evidence for a multiple sclerosis prodrome. <i>Nature Reviews Neurology</i> , 2019, 15, 689-690.	4.9	5
329	Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e033599.	0.8	5
330	Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1102-1110.	1.4	5
331	Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 239-249.	1.4	5
332	Development and internal validation of a multimorbidity index that predicts healthcare utilisation using the Canadian Longitudinal Study on Aging. <i>BMJ Open</i> , 2020, 10, e033974.	0.8	5
333	New applications for independent activities of daily living in measuring disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 97-106.	1.4	5
334	A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110211.	1.5	5
335	Examining cognitive speed and accuracy dysfunction in youth and young adults with pediatric-onset multiple sclerosis using a computerized neurocognitive battery.. <i>Neuropsychology</i> , 2021, 35, 388-398.	1.0	5
336	Disease-modifying therapies as cognition-modifying therapies? Treating cognitive impairment in MS. <i>Neurology</i> , 2020, 94, 957-958.	1.5	5
337	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. <i>BMC Neurology</i> , 2021, 21, 418.	0.8	5
338	Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data. <i>Frontiers in Neurology</i> , 2021, 12, 754144.	1.1	5
339	Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2022, 28, 16-28.	1.4	5
340	Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease. <i>General Hospital Psychiatry</i> , 2022, 77, 21-28.	1.2	5
341	No Evidence for Impairment of Venous Hemodynamics in Children or Young Adults with Pediatric-Onset Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2013, 34, 2366-2372.	1.2	4
342	Predictors of ICU Admission and Outcomes 1 Year Post-Admission in Persons with IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	4

#	ARTICLE	IF	CITATIONS
343	A gestational dose of vitamin D per day keeps the MS doctor away. <i>Neurology</i> , 2017, 88, 13-14.	1.5	4
344	Markedly increased incidence of critical illness in adults with Type 1 diabetes. <i>Diabetic Medicine</i> , 2017, 34, 1414-1420.	1.2	4
345	Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study. <i>BMJ Open</i> , 2017, 7, e018612.	0.8	4
346	Increased relapse rate during pregnancy and postpartum in neuromyelitis optica. <i>Neurology</i> , 2017, 89, 2220-2221.	1.5	4
347	Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e499.	3.1	4
348	Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101387.	0.9	4
349	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 138-144.	0.9	4
350	Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e84.	1.8	4
351	Feasibility of Using a Nationally Representative Telephone Survey to Monitor Multiple Sclerosis Prevalence in the United States. <i>Neuroepidemiology</i> , 2020, 54, 123-130.	1.1	4
352	Predictors of hospitalization in a Canadian MS population: A matched cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102028.	0.9	4
353	Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1781-1789.	1.4	4
354	Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 680-686.	1.0	4
355	Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103249.	0.9	4
356	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. <i>Frontiers in Immunology</i> , 2021, 12, 794075.	2.2	4
357	The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1299-1310.	1.4	4
358	Associations between courses of posttraumatic stress disorder and physical health conditions among Canadian military personnel. <i>Journal of Anxiety Disorders</i> , 2022, 87, 102543.	1.5	4
359	Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, 874724.	1.1	4
360	Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211020.	0.5	4

#	ARTICLE	IF	CITATIONS
361	A Systematic Review of the Validity and Reliability of the Patient-Determined Disease Steps Scale. <i>International Journal of MS Care</i> , 2023, 25, 20-25.	0.4	4
362	Relapses in multiple sclerosis. <i>Neurology</i> , 2009, 73, 1612-1613.	1.5	3
363	Observational studies of treatment effectiveness: useful, useless or somewhere in between?. <i>Multiple Sclerosis Journal</i> , 2013, 19, 707-708.	1.4	3
364	Neurological Registry Feasibility and Sustainability. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S55-S59.	0.3	3
365	Predictors of Fear of Sexual Rejection in Individuals with Multiple Sclerosis. <i>Sexuality and Disability</i> , 2015, 33, 53-61.	0.4	3
366	Harnessing real-world data to inform treatment decisions in multiple sclerosis. <i>Neurology</i> , 2019, 93, 285-286.	1.5	3
367	Adjusting for differential misclassification in matched case-control studies utilizing health administrative data. <i>Statistics in Medicine</i> , 2019, 38, 3669-3681.	0.8	3
368	Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2021, 23, 239-244.	0.4	3
369	Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2021, 3, 889-896.	0.9	3
370	You get what you measure. <i>Neurology</i> , 2008, 71, 620-621.	1.5	2
371	Cognitive test results in pediatric MS. <i>Neurology</i> , 2010, 75, 2054-2055.	1.5	2
372	Children of chronically ill parents: the silence of research. <i>Child: Care, Health and Development</i> , 2014, 40, 753-754.	0.8	2
373	Declines in the diagnosis of primary progressive MS: A critical change in phenotype or critical measurement error?. <i>Multiple Sclerosis Journal</i> , 2016, 22, 983-985.	1.4	2
374	The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 23-33.	1.4	2
375	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. <i>BMJ Open</i> , 2017, 7, e016276.	0.8	2
376	Maternal and fetal risks of natalizumab exposure in utero. <i>Neurology</i> , 2018, 90, 443-444.	1.5	2
377	Serum neurofilament light chain in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e421.	3.1	2
378	Identifying people with multiple sclerosis in the Canadian Primary Care Sentinel Surveillance Network. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989436.	0.5	2

#	ARTICLE	IF	CITATIONS
379	Author response: Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. <i>Neurology</i> , 2019, 93, 1081-1082.	1.5	2
380	Does age at diagnosis influence the use of health services for multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102555.	0.9	2
381	Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 481-487.	1.0	2
382	Factors Associated With Social Participation in Persons Living With Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 59-67.	0.1	2
383	Administrative data for observational research in multiple sclerosis: Opportunities and challenges. <i>Multiple Sclerosis Journal</i> , 2022, 28, 3-6.	1.4	2
384	Incidence of neurological and psychiatric comorbidity over time: a population-based cohort study in Ontario, Canada. <i>Age and Ageing</i> , 2022, 51, .	0.7	2
385	Health care utilisation before and after intensive care unit admission in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 975-982.	0.4	2
386	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1819-1824.	1.4	2
387	Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103779.	0.9	2
388	Progressive retinal changes in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103761.	0.9	2
389	Appraisal of the multiple sclerosis functional composite. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 335-341.	1.4	1
390	Multiple sclerosis and risk-taking. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 63-63.	0.2	1
391	Administrative databases for observational studies in multiple sclerosis: power or peril?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1151-1152.	1.4	1
392	Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case-control study. <i>BMC Health Services Research</i> , 2015, 15, 161.	0.9	1
393	Multiple sclerosis in First Nations Canadians: A pilot comparison study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731666609.	0.5	1
394	Increased Incidence of Critical Illness in Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 395-400.	0.6	1
395	Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. <i>CMAJ Open</i> , 2018, 6, E637-E642.	1.1	1
396	Obesity and brain volume loss in multiple sclerosis. <i>Neurology</i> , 2018, 91, 1079-1080.	1.5	1

#	ARTICLE	IF	CITATIONS
397	Contesting Medical Miracles: A Collective Action Framing Analysis of CCSVI and Venous Angioplasty (â€œLiberation Therapyâ€) for People With Multiple Sclerosis in News and Social Media. Science Communication, 2018, 40, 469-498.	1.8	1
398	Ten-year trajectories of health care utilization by Manitobans with MS predict nursing home entry. Neurology: Clinical Practice, 2019, 9, 16-23.	0.8	1
399	Interaction of HLA-DRB1*1501 and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis. Immunology and Infectious Diseases, 2013, 1, 10-17.	0.1	1
400	A Population-based Study of Grade 12 Academic Performance in Adolescents With Childhood-onset Chronic Rheumatic Diseases. Journal of Rheumatology, 2022, 49, 299-306.	1.0	1
401	Development of an indicator of smoking status for people with multiple sclerosis in administrative data. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210742.	0.5	1
402	Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits. Multiple Sclerosis Journal, 2022, 28, 1825-1828.	1.4	1
403	A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. International Journal of MS Care, 2021, 23, 245-252.	0.4	1
404	The epidemiology of multiple sclerosis. , 0, , 46-55.		0
405	Intensive care unit admission in multiple sclerosis: Increased incidence and increased mortality. Neurology, 2014, 83, 2192-2193.	1.5	0
406	Antinuclear antibodies in pediatric acquired demyelinating diseases of the central nervous system. Multiple Sclerosis Journal, 2014, 20, 1665-1666.	1.4	0
407	Care of persons with MS in clinical practice. Neurology: Clinical Practice, 2016, 6, 288-290.	0.8	0
408	Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology: Clinical Practice, 2016, 6, 201-202.	0.8	0
409	Author response: High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology, 2017, 89, 1429-1430.	1.5	0
410	Recognizing the diversity gap in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1425-1426.	1.4	0
411	Physical Activity and Sedentary Behavior Patterns Across Weekdays and Weekend Days in Youth With Multiple Sclerosis and Controls. International Journal of MS Care, 2022, 24, 8-12.	0.4	0
412	Effect of Physical Comorbidities on Risk of Depression in Multiple Sclerosis. International Journal of MS Care, 2013, 15, 34-43.	0.4	0
413	Reproductive Issues in Multiple Sclerosis: Parental MS and Child Outcomes (The Research Perspective). , 2017, , 63-72.		0
414	Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study. Child Neuropsychology, 2021, , 1-22.	0.8	0



#	ARTICLE	IF	CITATIONS
415	Control charts for chronic disease surveillance: testing algorithm sensitivity to changes in data coding. BMC Public Health, 2022, 22, 406.	1.2	0
416	Guest Editorial. International Journal of MS Care, 2021, 23, iva-iv.	0.4	0
417	Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 747853.	1.1	0
418	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0
419	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0
420	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0
421	Health service utilization in immigrants with multiple sclerosis. , 2020, 15, e0234876.		0